Recent studies have demonstrated the clinical utility of continuous glucose monitoring (CGM) use in type 2 diabetes (T2D) patients who are treated with intensive insulin management. Large retrospective database analyses of T2D patients treated with less-intensive therapies have also shown that CGM use was associated with significant reductions in hemoglobin A1c levels and health resource utilization, including diabetes-related hospitalizations and emergency room care. Despite the growing body of evidence supporting CGM use in the broader T2D population, current eligibility criteria required by public and many private insurers are denying millions of individuals with T2D access to this valuable technology. In this article, we discuss an evidence-based rationale for modifying current eligibility requirements for CGM coverage.

中文翻译：

---

连续血糖监测 (CGM) 是一种工具，而不是奖励：不合理的保险范围标准限制了对 CGM 的访问

最近的研究表明，连续血糖监测 (CGM) 在接受强化胰岛素管理治疗的 2 型糖尿病 (T2D) 患者中的临床效用。对接受低强度治疗的 T2D 患者进行的大型回顾性数据库分析也表明，CGM 的使用与血红蛋白 A1c 水平和健康资源利用率的显着降低有关，包括与糖尿病相关的住院和急诊室护理。尽管越来越多的证据支持 CGM 在更广泛的 T2D 人群中使用，但公共和许多私人保险公司要求的当前资格标准正在拒绝数百万患有 T2D 的人使用这种有价值的技术。在本文中，我们讨论了修改当前 CGM 覆盖范围的资格要求的基于证据的基本原理。